Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Trial of Pirtobrutinib Treatment (24 Cycles) With 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. ODYSSEUS Study (Outcome-Driven Trial for Relapsed CLL/SLL Combining BTK and Bispecific antibodY to Improve Outcome)

NCT07860775 is registered in ClinicalTrials.gov with Stichting Hemato-Oncologie voor Volwassenen Nederland as lead sponsor.

NCT NCT07860775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07860775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Trial of Pirtobrutinib Treatment (24 Cycles) With 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. ODYSSEUS Study (Outcome-Driven Trial for Relapsed CLL/SLL Combining BTK and Bispecific antibodY to Improve Outcome)
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
October 15, 2032
Enrollment
70 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cll / sll